Can Postbiotics Represent a New Strategy for NEC?

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Increasing evidence indicates that many of the health beneficial effects associated with the establishment of a symbiotic gut microbiota are driven by bacterial metabolic by-products. The term “postbiotics” indicates any soluble factor resulting from the metabolic activity of a live bacteria or any released molecule capable of providing health benefits through a direct or indirect mechanism. Alterations in preterm gut colonization associated with the intestinal barrier immaturity and the increased reactivity of the intestinal mucosa to colonizing bacteria have been implicated in the pathogenesis of necrotizing enterocolitis. Recent advances in the comprehension of the postbiotic biological effects and related mechanisms, some of them reviewed here, indicate that postbiotics may be a promising effective preventive strategy against necrotizing enterocolitis while avoiding the risk of administering live microorganisms to preterm infants that could translocate and cause infection. However, data from trials investigating the efficacy of postbiotics for the prevention of necrotizing enterocolitis in preterm infants are needed, and issues regarding their optimal regimen and start and duration of treatment need to be addressed.

Original languageEnglish
Title of host publicationAdvances in Experimental Medicine and Biology
PublisherSpringer New York LLC
Pages37-45
Number of pages9
Volume1125
DOIs
Publication statusPublished - Jan 1 2019

Publication series

NameAdvances in Experimental Medicine and Biology
Volume1125
ISSN (Print)0065-2598
ISSN (Electronic)2214-8019

Fingerprint

Necrotizing Enterocolitis
Bacteria
Health
Premature Infants
Microorganisms
Byproducts
Insurance Benefits
Intestinal Mucosa
Molecules
Infection
Therapeutics
Mucous Membrane

Keywords

  • Microbiota
  • Necrotizing enterocolitis
  • Postbiotics
  • Preventive strategy
  • Signaling

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Mosca, F., Gianni, M. L., & Rescigno, M. (2019). Can Postbiotics Represent a New Strategy for NEC? In Advances in Experimental Medicine and Biology (Vol. 1125, pp. 37-45). (Advances in Experimental Medicine and Biology; Vol. 1125). Springer New York LLC. https://doi.org/10.1007/5584_2018_314

Can Postbiotics Represent a New Strategy for NEC? / Mosca, Fabio; Gianni, Maria Lorella; Rescigno, Maria.

Advances in Experimental Medicine and Biology. Vol. 1125 Springer New York LLC, 2019. p. 37-45 (Advances in Experimental Medicine and Biology; Vol. 1125).

Research output: Chapter in Book/Report/Conference proceedingChapter

Mosca, F, Gianni, ML & Rescigno, M 2019, Can Postbiotics Represent a New Strategy for NEC? in Advances in Experimental Medicine and Biology. vol. 1125, Advances in Experimental Medicine and Biology, vol. 1125, Springer New York LLC, pp. 37-45. https://doi.org/10.1007/5584_2018_314
Mosca F, Gianni ML, Rescigno M. Can Postbiotics Represent a New Strategy for NEC? In Advances in Experimental Medicine and Biology. Vol. 1125. Springer New York LLC. 2019. p. 37-45. (Advances in Experimental Medicine and Biology). https://doi.org/10.1007/5584_2018_314
Mosca, Fabio ; Gianni, Maria Lorella ; Rescigno, Maria. / Can Postbiotics Represent a New Strategy for NEC?. Advances in Experimental Medicine and Biology. Vol. 1125 Springer New York LLC, 2019. pp. 37-45 (Advances in Experimental Medicine and Biology).
@inbook{b042c956549f495d922120a628f37ad2,
title = "Can Postbiotics Represent a New Strategy for NEC?",
abstract = "Increasing evidence indicates that many of the health beneficial effects associated with the establishment of a symbiotic gut microbiota are driven by bacterial metabolic by-products. The term “postbiotics” indicates any soluble factor resulting from the metabolic activity of a live bacteria or any released molecule capable of providing health benefits through a direct or indirect mechanism. Alterations in preterm gut colonization associated with the intestinal barrier immaturity and the increased reactivity of the intestinal mucosa to colonizing bacteria have been implicated in the pathogenesis of necrotizing enterocolitis. Recent advances in the comprehension of the postbiotic biological effects and related mechanisms, some of them reviewed here, indicate that postbiotics may be a promising effective preventive strategy against necrotizing enterocolitis while avoiding the risk of administering live microorganisms to preterm infants that could translocate and cause infection. However, data from trials investigating the efficacy of postbiotics for the prevention of necrotizing enterocolitis in preterm infants are needed, and issues regarding their optimal regimen and start and duration of treatment need to be addressed.",
keywords = "Microbiota, Necrotizing enterocolitis, Postbiotics, Preventive strategy, Signaling",
author = "Fabio Mosca and Gianni, {Maria Lorella} and Maria Rescigno",
year = "2019",
month = "1",
day = "1",
doi = "10.1007/5584_2018_314",
language = "English",
volume = "1125",
series = "Advances in Experimental Medicine and Biology",
publisher = "Springer New York LLC",
pages = "37--45",
booktitle = "Advances in Experimental Medicine and Biology",
address = "United States",

}

TY - CHAP

T1 - Can Postbiotics Represent a New Strategy for NEC?

AU - Mosca, Fabio

AU - Gianni, Maria Lorella

AU - Rescigno, Maria

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Increasing evidence indicates that many of the health beneficial effects associated with the establishment of a symbiotic gut microbiota are driven by bacterial metabolic by-products. The term “postbiotics” indicates any soluble factor resulting from the metabolic activity of a live bacteria or any released molecule capable of providing health benefits through a direct or indirect mechanism. Alterations in preterm gut colonization associated with the intestinal barrier immaturity and the increased reactivity of the intestinal mucosa to colonizing bacteria have been implicated in the pathogenesis of necrotizing enterocolitis. Recent advances in the comprehension of the postbiotic biological effects and related mechanisms, some of them reviewed here, indicate that postbiotics may be a promising effective preventive strategy against necrotizing enterocolitis while avoiding the risk of administering live microorganisms to preterm infants that could translocate and cause infection. However, data from trials investigating the efficacy of postbiotics for the prevention of necrotizing enterocolitis in preterm infants are needed, and issues regarding their optimal regimen and start and duration of treatment need to be addressed.

AB - Increasing evidence indicates that many of the health beneficial effects associated with the establishment of a symbiotic gut microbiota are driven by bacterial metabolic by-products. The term “postbiotics” indicates any soluble factor resulting from the metabolic activity of a live bacteria or any released molecule capable of providing health benefits through a direct or indirect mechanism. Alterations in preterm gut colonization associated with the intestinal barrier immaturity and the increased reactivity of the intestinal mucosa to colonizing bacteria have been implicated in the pathogenesis of necrotizing enterocolitis. Recent advances in the comprehension of the postbiotic biological effects and related mechanisms, some of them reviewed here, indicate that postbiotics may be a promising effective preventive strategy against necrotizing enterocolitis while avoiding the risk of administering live microorganisms to preterm infants that could translocate and cause infection. However, data from trials investigating the efficacy of postbiotics for the prevention of necrotizing enterocolitis in preterm infants are needed, and issues regarding their optimal regimen and start and duration of treatment need to be addressed.

KW - Microbiota

KW - Necrotizing enterocolitis

KW - Postbiotics

KW - Preventive strategy

KW - Signaling

UR - http://www.scopus.com/inward/record.url?scp=85067600379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067600379&partnerID=8YFLogxK

U2 - 10.1007/5584_2018_314

DO - 10.1007/5584_2018_314

M3 - Chapter

VL - 1125

T3 - Advances in Experimental Medicine and Biology

SP - 37

EP - 45

BT - Advances in Experimental Medicine and Biology

PB - Springer New York LLC

ER -